[Docetaxel and gastric cancer]

Related Experiment Video

Updated: Aug 24, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Michel Ducreux1, Valérie Boige, Arnaud Roth

  • 1Unité de gastroentérologie, Institut Gustave-Roussy, rue Camille-Desmoulins, 94805 Villejuif. ducreux@igr.fr

Bulletin Du Cancer
|June 3, 2004
PubMed

Insights

Docetaxel shows significant promise for metastatic gastric cancer, with a 20% response rate in monotherapy. Combination therapies, including docetaxel-cisplatin and TCF, are being evaluated for improved treatment outcomes.

Area of Science:

  • Oncology
  • Medical Chemistry

Background:

  • Limited effective treatments exist for metastatic gastric carcinoma.
  • Docetaxel emerges as a promising agent with notable activity.

Purpose of the Study:

  • To evaluate the efficacy of docetaxel in monotherapy and combination regimens for gastric cancer.
  • To explore the potential of docetaxel in neoadjuvant, adjuvant, and radiochemotherapy settings.

Main Methods:

  • Objective response evaluation of docetaxel monotherapy.
  • Assessment of combination therapies: docetaxel-cisplatin and docetaxel, 5-fluorouracil (5FU), cisplatin (TCF).
  • Ongoing Phase III trials comparing new schedules with classical chemotherapies (5FU-cisplatin, ECF).

Main Results:

  • Docetaxel demonstrated a 20% response rate in monotherapy for metastatic gastric carcinoma.
  • Favorable toxicity profile allows combination therapies.
  • TCF regimen is under evaluation for resectable gastric cancer (neoadjuvant/adjuvant).

Conclusions:

  • Docetaxel is a significant drug for metastatic gastric cancer treatment.
  • Combination therapies involving docetaxel show potential for improved outcomes.
  • Docetaxel's radiosensitizing properties suggest a role in future radiochemotherapy protocols.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...